News & Updates

A lifestyle pattern with higher insulinemic potential may predispose an individual to endometrial cancer (EC), suggests a study.

Treatment with the combination of zanidatamab plus palbociclib and fulvestrant is safe and demonstrates promising antitumour activity in patients with HR-positive, HER2-positive advanced or metastatic breast cancer, according to a phase IIa study.

Patients with inflammatory bowel disease (IBD) appear to be at heightened risk of rheumatoid arthritis (RA), as reported in a study.

Both drotaverine and peppermint oil are safe and help alleviate abdominal pain in children whose pain cannot be attributed to a specific medical condition, with neither treatment demonstrating clear superiority over the other, according to the results of a single-blind, randomized controlled trial.

A nurse-led mobile health (mHealth) intervention that utilizes basic phones improves blood pressure (BP) control among stroke survivors in Ghana, as shown in the phase III PINGS-2 trial.

Postmenopausal women who engage in healthy lifestyle behaviours appear to have a reduced risk of breast cancer, regardless of race and ethnicity and hormone receptor status, according to a study.

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), anlotinib plus pepulimab appears to significantly increase progression-free survival (PFS) and overall survival (OS) compared with sorafenib, as shown in the results of the phase III APOLLO study conducted in China.